Cota reels in $40M in series C funding to advance its analytics program

20 dollar bills
Cota reeled in $40 million in series C funding to advance its analytics program. (StockSnap)

Cota, a healthcare data analytics company, raised $40 million in series C financing. The company said the funds will be used to advance its Cota Nodal Address (CNA) disease classification system.

The round of funding was led by IQVIA. EW Healthcare Partners was also a major participant. Joining in the funding round were Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health and Atoc Holdings.

The company said the money will be used to scale its product across providers, payers and life science companies. The company describes its CNA product as a “precision disease classification system” developed using comprehensive real-world data.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"With our CNA classification system and powerful analytics, we are confident that Cota will revolutionize both patient care and healthcare economics,” John Hervey, Cota’s chief executive, said in a statement. “The depth and richness of our real-world evidence set empowers life sciences companies to gain new insights into their compounds, accelerate market applications and support clinical trials.”

As the lead in the round, IQVIA received a seat on Cota's board of directors.


Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Exact Sciences received an FDA breakthrough designation for its liver cancer blood test as it finalized its $2.8 billion merger with Genomic Health.